A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Wolman disease
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals; Synageva BioPharma
- 29 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 15 Feb 2019 The trial has been completed in UK.
- 12 Dec 2018 This trial has been completed in Finland (end date: 2018-10-30)